Results 41 to 50 of about 2,763 (183)
The Journal of Headache and Pain, 2021 Background Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor.
Stewart J. Tepper +7 more
doaj +1 more source
Cephalalgia Reports, 2021 Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine.
Stewart J Tepper +6 more
doaj +1 more source
Erenumab in Mechanism-based Migraine Treatment
, 2021 Migraine is a type of primary headache with recurrent attacks, negatively affects the daily living activities of sufferers because of its severity, and causes a heavy economic burden.
Uluduz, Derya +3 more
core +1 more source
Predictors of clinical response to erenumab in patients with migraine
Cephalalgia Reports, 2022 Background: Anti-CGRP monoclonal antibodies have emerged as efficacious preventive therapies for some, but not all patients with migraine. It is not yet fully understood what predicts treatment response.
Olga Lekontseva +2 more
doaj +1 more source
Neurologijos seminarai, 2023 Background. Migraine is a primary headache disorder described by episodic attacks that can progress to chronic migraine. Preventive treatment of anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) is currently being widely ...
V. Karpavičiūtė +2 more
doaj +3 more sources
Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data
, 2022 Background: Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor which has been found effective even for the treatment of chronic migraine (CM) complicated with medication overuse headache (MOH).
Pani L. +7 more
core +2 more sources
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Predictors of response to erenumab after 12 months of treatment [PDF]
, 2021 Objective: Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor and approved for the preventive treatment of chronic migraine.
Pani L. +4 more
core +3 more sources
Frontiers in Neurology, 2021 Erenumab is the first human monoclonal antibody to be approved as a selective therapy for migraine prophylaxis in adults. This study assessed, in a real-world setting, the efficacy of erenumab and its impact on the quality of life (QoL) of Cypriot ...
Andria Tziakouri +3 more
doaj +1 more source
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Objective To present a practical, evidence‐based framework for the management of headache disorders in pediatric patients with prior stroke or underlying cerebral vascular lesions, with particular attention to safety and efficacy of pharmacologic and non‐pharmacologic therapies.
Allison C. Hyland +7 more
wiley +1 more source